Crohn’s & Colitis Congress™

Sessions Speakers Exhibitors Floor Plan Buzz

Sessions (12)

View/Sort by Tracks | Day

List

Keynote Clinical Presentation: How to Incorporate New Therapies into Current Practice (Room Pinyon 4/5)

19 Jan 18

2:00 PM - 2:20 PM

Tracks: Session II

Speaker(s): Edward Loftus, Jr. MD, AGAF

More...

Question and Answer (Room Pinyon 3)

19 Jan 18

5:10 PM - 5:20 PM

Tracks: Session II

More...

Question and Answer (Room Pinyon 4/5)

19 Jan 18

5:10 PM - 5:20 PM

Tracks: Session II

More...

13 - REFINED POPULATION PHARMACOKINETIC MODEL FOR INFLIXIMAB PRECISION DOSING IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (Room Pinyon 4/5)

19 Jan 18

2:20 PM - 2:30 PM

Tracks: Defining Optimal Treatment Algorithms, Session II

Speaker(s): Laura Bauman

Background: Standard weight-based infliximab (IFX) dosing for inflammatory bowel disease (IBD) results in long-term clinical remission in only 40-6... More...

Keynote Research Presentation: Biomarkers for Precision Medicine (Room Pinyon 4/5)

19 Jan 18

2:30 PM - 2:50 PM

Tracks: Session II

Speaker(s): Lee Denson MD

More...

14 - POST-HOC ANALYSIS OF TOFACITINIB CROHN’S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION (Room Pinyon 4/5)

19 Jan 18

2:50 PM - 3:00 PM

Tracks: Defining Optimal Treatment Algorithms, Session II

Speaker(s): Bruce Sands MD, MS, AGAF

Background: Tofacitinib is an oral, small molecule Janus kinase (JAK) inhibitor that is being investigated for IBD. In a recent trial of Crohn&rsqu... More...

Multidisciplinary Panel Review of Cases (Room Pinyon 4/5)

19 Jan 18

3:20 PM - 4:10 PM

Tracks: Session II

Speaker(s): Alessandro Fichera MD ; Eva Szigethy MD, PhD ; Fabrizio Michelassi MD ; James Lewis MD, MSCE, AGAF ; Jean Frederic Colombel MD ; Jeffrey Hyams MD ; Kelly Issokson MS, RD, CNSC

Click or tap case titles to download: Case 1: 18-Year Old Patient with Newly-Diagnosed Mild to Moderate Crohn’s Disease With On... More...